NCT07679321 The Impact of Anxiety/Depression on the Efficacy of Asthma Control Drugs and the Construction of a Predictive Model for the Risk of Acute Asthma Attacks
| NCT ID | NCT07679321 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiangya Hospital of Central South University |
| Condition | Anxiety/Depression and Asthma |
| Study Type | OBSERVATIONAL |
| Enrollment | 256 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2027-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 256 participants in total. It began in 2024-12-01 with a primary completion date of 2027-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to explore the impact of anxiety/depression on the efficacy of asthma controller medications and to develop a risk prediction model for asthma acute exacerbations in patients with asthma. It will also analyze the association between anxiety/depression severity and asthma severity. The main questions it aims to answer are: Does anxiety/depression affect the therapeutic effect of asthma controller medications (e.g., asthma control level)? Can a reliable risk prediction model for asthma acute exacerbations be established based on anxiety/depression and other relevant factors? Researchers will conduct a prospective observational study to collect and analyze data from participants, without additional interventions beyond standard clinical care, to explore the above research questions. Participants will: Complete baseline assessments, including demographic information collection, medical history review, lung function tests, anxiety/depression evaluations (via GAD-7 and PHQ-9 scales), and provide biological samples (induced sputum, feces, blood) Undergo follow-up visits at 3, 6, 12, 18, and 24 months after baseline Report asthma symptoms, acute exacerbation events, and cooperate with required clinical checkups during follow-up
Eligibility Criteria
Inclusion Criteria: * Diagnosis of asthma according to the Global Initiative for Asthma (GINA) 2024 criteria. * Male or female patients aged 14 years or older. * Complete clinical data available. * Newly diagnosed asthma or stable asthma. * Receiving asthma controller medication. Exclusion Criteria: * History of major lung diseases other than asthma, congestive heart failure, cor pulmonale, or recent cardiac or thoracic surgery. * Incomplete medical records. * Cognitive impairment or inability to complete psychological scale assessments. * Clinically diagnosed acute or chronic mental disorders, such as bipolar disorder or schizophrenia. * Current use of antidepressant or anti-anxiety medications. * Pregnancy or lactation.
Frequently Asked Questions
Who can join the NCT07679321 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying Anxiety/Depression and Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07679321 currently recruiting?
Yes, NCT07679321 is actively recruiting participants. Visit ClinicalTrials.gov or contact Xiangya Hospital of Central South University to inquire about joining.
Where is the NCT07679321 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT07679321 clinical trial?
NCT07679321 is sponsored by Xiangya Hospital of Central South University. The trial plans to enroll 256 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.